Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without LapatinibLisa A. Carey, Clifford A. Hudis, Donald A. Berry et al.|Journal of Clinical Oncology|2015Cited by 440
Treg depletion potentiates checkpoint inhibition in claudin-low breast cancerNicholas Taylor, Jonathan S. Serody, Sarah C. Vick et al.|Journal of Clinical Investigation|2017Cited by 143
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast CancerJonathan T. Lei, Matthew J. Ellis, Meenakshi Anurag et al.|Cell Reports|2018Cited by 110